AB Science's Focused Strategy Earns Analyst Confidence and a €4.25 Target

PARIS, FRANCE – June 02, 2026 – In a market that often punishes uncertainty, French pharmaceutical firm AB Science has received a significant vote of confidence. Stonegate Capital Partners, a US-based research firm, has updated its coverage, assigning the stock a mid-point valuation of €4.25 per share. The move follows a period of strategic realignment for AB Science, which has sharpened its focus onto its most promising clinical assets while shoring up its financial position through disciplined capital management and innovative risk-mitigation tools.

This updated analysis provides more than just a new number; it validates a corporate strategy that prioritizes depth over breadth, concentrating the company's resources on two of the most challenging frontiers in modern medicine: Amyotrophic Lateral Sclerosis (ALS) and Acute Myeloid Leukemia (AML). For investors and industry observers, the question is no longer just about the science, but whether this newfound focus and financial prudence can successfully navigate the notoriously difficult path to regulatory approval and commercial success.

Behind the Bullish Valuation

Stonegate’s valuation, which ranges from €3.20 to €5.77 per share, is derived from a discounted cash flow (DCF) model—a standard but assumption-heavy methodology that projects a company's future financial performance. What makes this particular analysis compelling is Stonegate's explicit note that its current model is intentionally "conservative." The firm suggests that successful de-risking, both on the regulatory and operational fronts, could warrant a lower discount rate, potentially doubling the valuation mid-point to approximately €8.50 per share.

This conditional upside speaks directly to the core challenge and opportunity facing AB Science. The current €4.25 target reflects the inherent risks of a clinical-stage biotech firm. The potential €8.50 figure represents the value that could be unlocked if the company executes on its strategy and its lead drug candidates deliver on their clinical promise. This positions the company at a critical inflection point, where near-term execution on its pivotal trials is paramount.

Stonegate Capital Partners specializes in providing research on small and micro-cap companies, often for an institutional audience. While it's standard practice for such firms to be compensated by the companies they cover, their analysis provides a detailed framework for evaluating assets that are often overlooked by larger Wall Street institutions. The report, alongside coverage from firms like Maxim Group and Chardan, solidifies a growing analyst consensus that AB Science's strategic direction is sound.

A Calculated Pivot to Core Assets

The foundation of this renewed confidence is AB Science's strategic reset. The company has publicly declared its two main priorities: its long-standing lead compound, masitinib, in a confirmatory Phase 3 trial for ALS, and a promising new asset, AB8939, for AML. This represents a significant clarification of its pipeline, which previously included more resource-intensive programs.

Notably, development programs for progressive multiple sclerosis (MS) and Alzheimer’s disease (AD) have been repositioned as "partnership-led opportunities." This is a pragmatic and increasingly common move for biotech firms of AB Science's size. Both MS and Alzheimer's are therapeutic areas characterized by colossal trial sizes, immense costs, and a high rate of clinical failure. By seeking partners, AB Science can potentially monetize these assets and mitigate its financial exposure, while dedicating its internal resources to the programs with the clearest path forward. This strategic discipline is reflected in the company's financials, with its operating loss declining a notable 38% to €3.8 million in its 2025 fiscal year.

The Clinical Gauntlet: Targeting Unmet Needs

Ultimately, a biotech's value is rooted in its ability to bring effective new medicines to patients. AB Science's future now rests heavily on two key clinical pillars.

First is masitinib, a protein kinase inhibitor that has been the company's workhorse for years. Its most advanced indication is in ALS, a devastating neurodegenerative disease with limited effective treatments. The company is proceeding with its FDA-authorized confirmatory Phase 3 trial, AB23005. The 408-patient study is designed to validate earlier findings that showed significant benefits in a specific subgroup of "normally progressing" ALS patients. The previous study reported a clinically meaningful slowing of functional decline, a 9-month benefit in progression-free survival, and a 12-month median overall survival benefit in this population. In a field where progress is measured in months, not cures, these are compelling figures that the new trial aims to confirm.

Second, and emerging as a vital second pillar, is AB8939 for Acute Myeloid Leukemia (AML). AML, particularly in relapsed or refractory patients, remains a significant challenge for oncologists. Early data for AB8939, used in combination with other agents, has been highly encouraging. In a small group of heavily pre-treated patients with difficult-to-treat genetics, the drug has shown responses in all four participants, including one complete remission. While it is crucial to emphasize that this is very early data from a small sample size, achieving a complete remission in this patient population is a powerful signal of a drug's potential activity. It provides a strong rationale for continued development and supports the company's strategy of building a second major asset beyond masitinib.

Fortifying the Financial Frontline

A focused strategy and promising science are only viable with the capital to execute. AB Science appears to be addressing this head-on. The company ended 2025 with €10.2 million in cash and bolstered that with a €3.2 million private placement in April 2026. While its cash burn has been managed down, the costs of a global Phase 3 trial remain substantial.

Here, the company has employed a sophisticated financial instrument to de-risk its most critical endeavor. It has secured an offer for Clinical Trial Financial Insurance (CTFI) for the AB23005 ALS trial. This policy provides €25 million in coverage, extendable to €39 million, to cover costs in the event of clinical failure. This is a game-changer. It not only protects the company's balance sheet from a catastrophic cash drain but also serves as an implicit third-party validation of the trial's design and statistical plan, as an insurer has deemed the risk profile acceptable. This shrewd financial maneuver provides a significant buffer, allowing management to focus on clinical execution rather than immediate fundraising pressures.

With a clearer strategy, a bolstered balance sheet, and two high-potential clinical programs aimed at significant unmet needs, AB Science has crafted a compelling narrative for its next chapter. The path of drug development is never certain, but the company has systematically addressed many of the key variables within its control, earning a deserved nod of approval from the analysts watching closely.